Posted by Michael Wonder on 03 Oct 2024
KalVista announces the submission of additional marketing authorisation applications for sebetralstat for the oral on-demand treatment of hereditary angioedema
30 September 2024 - If approved, sebetralstat will be the first, oral on-demand treatment for HAE.
KalVista Pharmaceuticals today announced marketing authorisation application submissions to the regulatory authorities in the United Kingdom, Switzerland, Australia, and Singapore for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema attacks in adults and adolescents aged 12 years and older.
